Malaz Abutarif

585 total citations
33 papers, 393 citations indexed

About

Malaz Abutarif is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Malaz Abutarif has authored 33 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Infectious Diseases. Recurrent topics in Malaz Abutarif's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Hepatitis C virus research (6 papers). Malaz Abutarif is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Hepatitis C virus research (6 papers). Malaz Abutarif collaborates with scholars based in United States, Japan and Germany. Malaz Abutarif's co-authors include Paul Statkevich, Fengjuan Xuan, Oliver A. Cornely, David Angulo, Monika Martinho, Gopal Krishna, Gopal Krishna, Τushar Garimella, Frank LaCreta and Ophelia Yin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Hepatology.

In The Last Decade

Malaz Abutarif

29 papers receiving 391 citations

Peers

Malaz Abutarif

ONCOL

EPIDE

PRM

Risto S Cvetkovi New Zealand

Hélène Sauvageon France

Iris M. De Cuyper Netherlands

Kurt R. Oettel United States

Francesca Romana Stefani Italy

Mark Matson United States

Ernestina Tetteh United States

David L. Hyslop United States

R. Schleyerbach Germany

Lusia Sepiashvili Canada

Risto S Cvetkovi New Zealand

Malaz Abutarif

137 ×0.9

ONCOL

43 ×0.3

97 ×0.8

EPIDE

54 ×0.7

PRM

91 ×1.4

Citations per year, relative to Malaz Abutarif Malaz Abutarif (= 1×) peers Risto S Cvetkovi

Countries citing papers authored by Malaz Abutarif

Since Specialization

Citations

This map shows the geographic impact of Malaz Abutarif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malaz Abutarif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malaz Abutarif more than expected).

Fields of papers citing papers by Malaz Abutarif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malaz Abutarif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malaz Abutarif. The network helps show where Malaz Abutarif may publish in the future.

Co-authorship network of co-authors of Malaz Abutarif

This figure shows the co-authorship network connecting the top 25 collaborators of Malaz Abutarif. A scholar is included among the top collaborators of Malaz Abutarif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malaz Abutarif. Malaz Abutarif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hong, Ying, Naoyuki Tajima, Hong Zebger‐Gong, et al.. (2025). Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Antibody‐Drug Conjugate, in Patients With Advanced Solid Tumors. CPT Pharmacometrics & Systems Pharmacology. 14(12). 2149–2160. 2 indexed citations

Tachibana, Masaya, Miho Kazui, Tomoko Ikeda, et al.. (2025). Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding. Cancer Chemotherapy and Pharmacology. 95(1). 54–54. 4 indexed citations

Xu, Yuan, Mark Lee, Xiaoning Wang, et al.. (2025). Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors. Clinical Pharmacokinetics. 64(6). 943–957. 1 indexed citations

Li, Hanbin, et al.. (2024). Abstract PO3-04-02: Exposure-efficacy and safety analysis of trastuzumab deruxtecan (T-DXd) in patients with advanced/metastatic HER2+ breast cancer (BC): Analyses from Phase 3 Studies DESTINY-Breast02 (DB-02) and DESTINY-Breast03 (DB-03). Cancer Research. 84(9_Supplement). PO3–4.

Vaddady, Pavan, et al.. (2024). Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia. Clinical and Translational Science. 17(11). e70065–e70065. 1 indexed citations

Vaddady, Pavan, et al.. (2024). Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia. Clinical and Translational Science. 17(12). e70074–e70074.

Cobbina, Enoch, et al.. (2024). Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). e20537–e20537.

Salas, Maribel, Jasmeet Singh, Yoshinori Kawaguchi, et al.. (2023). Use of Real‐World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2–Targeted Antibody–Drug Conjugate in Gastric Cancer. The Journal of Clinical Pharmacology. 63(11). 1244–1255. 1 indexed citations

Kobayashi, Yoshimasa, Stefanie Hennig, Helen Kastrissios, et al.. (2023). Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2‐Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure–Response Analysis. The Journal of Clinical Pharmacology. 63(11). 1232–1243. 9 indexed citations

10.

Tajima, Naoyuki, et al.. (2022). Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. The Journal of Clinical Pharmacology. 63(1). 77–90. 6 indexed citations

11.

Kang, Dongwoo, Elizabeth Ludwig, Hannah Huang, et al.. (2021). Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 87(4). 513–523. 9 indexed citations

12.

Yin, Ophelia, et al.. (2020). Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors. Clinical Pharmacology & Therapeutics. 109(5). 1314–1325. 35 indexed citations

13.

Zhu, Li, Hanbin Li, Phyllis Chan, et al.. (2018). Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious Diseases and Therapy. 7(2). 261–275. 4 indexed citations

14.

Garimella, Τushar, Xiaolu Tao, Karen Sims, et al.. (2017). Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects. Drugs in R&D. 18(1). 55–65. 20 indexed citations

15.

Chan, Phyllis, Hanbin Li, Li Zhu, et al.. (2017). Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clinical Pharmacokinetics. 56(10). 1173–1183. 11 indexed citations

16.

Sims, Karen, Michael Hesney, Megan Wind‐Rotolo, et al.. (2015). P0790 : The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir. Journal of Hepatology. 62. S628–S628. 5 indexed citations

17.

Diez, Blanca, Paul Statkevich, Yali Zhu, et al.. (2009). Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemotherapy and Pharmacology. 65(4). 727–734. 44 indexed citations

18.

Krishna, Gopal, Malaz Abutarif, Fengjuan Xuan, et al.. (2008). Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(10). 1223–1232. 82 indexed citations

19.

Abutarif, Malaz & David R. Taft. (2002). Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Erythrocyte Carbonic Anhydrase Binding on Drug Disposition. Pharmaceutical Research. 19(4). 551–555. 1 indexed citations

20.

Almoazen, Hassan, et al.. (2001). Alternative high-performance liquid chromatographic assay for p-aminohippuric acid (PAH): effect of aging on PAH excretion in the isolated perfused rat kidney. Journal of Pharmaceutical and Biomedical Analysis. 26(5-6). 687–699. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact